| A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer (NCT05395780) | Maxinovel Pty., Ltd. | 2022-06-01 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (NCT05322577) | Amgen | 2022-05-17 |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (NCT05494060) | The First Affiliated Hospital with Nanjing Medical University | 2022-03-16 |
| Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma (NCT05439993) | Hallym University Medical Center | 2022-03-01 |
| A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (NCT04931654) | AstraZeneca | 2021-09-28 |
| Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction (NCT06250894) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-03-30 |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection (NCT04510285) | Memorial Sloan Kettering Cancer Center | 2020-08-10 |
| STRENGTH Expansion (NCT04520867) | University of Colorado, Denver | 2020-08-06 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (NCT04882241) | Merck Sharp & Dohme LLC | 2020-07-29 |
| A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (NCT04396821) | Suzhou Transcenta Therapeutics Co., Ltd. | 2020-05-28 |
| Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab (NCT04276493) | BeiGene | 2020-03-26 |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (NCT04082364) | MacroGenics | 2019-09-30 |
| Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ (NCT04061928) | Peking University | 2019-08-26 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma. (NCT03529266) | Sun Yat-sen University | 2018-06-01 |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (NCT03526835) | Merus B.V. | 2018-05-02 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (NCT03221426) | Merck Sharp & Dohme LLC | 2017-10-09 |
| Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (NCT02872116) | Bristol-Myers Squibb | 2016-10-12 |
| Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer (NCT02501603) | Yonsei University | 2016-07-01 |
| FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (NCT02661971) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2016-06-01 |
| FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (NCT02581462) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2016-06-01 |
| Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer (NCT02726399) | Memorial Sloan Kettering Cancer Center | 2016-03-18 |
| PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy (NCT02433301) | Rikshospitalet University Hospital | 2015-04-01 |
| Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer (NCT02085564) | Rigshospitalet, Denmark | 2014-03-01 |
| A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer (NCT02027948) | Memorial Sloan Kettering Cancer Center | 2013-12-23 |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer (NCT01813253) | Kuhnil Pharmaceutical Co., Ltd. | 2013-05-13 |
| Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (NCT01743365) | Hellenic Cooperative Oncology Group | 2013-02-11 |
| A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer (NCT01748773) | Hoffmann-La Roche | 2013-01-29 |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach (NCT01774851) | Merrimack Pharmaceuticals | 2013-01-01 |
| Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer (NCT01747707) | Chinese Academy of Medical Sciences | 2012-09-01 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
| Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea (NCT02538562) | Hoffmann-La Roche | 2011-10-11 |
| Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer (NCT00917462) | Memorial Sloan Kettering Cancer Center | 2009-06-01 |